Mercury Laboratories Ltd

Appointment: Sunil Sharma - HOD Injectables

• Sunil Sharma appointed HOD, Dept.-Injectable Production; 45, B.Pharm; 19+ years in injectable production; full-time; effective 21 Aug 2026.

Resignation: Seema Salvi from SMP and HOD Injectables

• Seema Salvi resigns as SMP and HOD-Injectable Production for better opportunities and career advancement; cessation 21 Aug 2026.

Dividend proposal & record date

• Board recommends dividend of Rs 3.5 per share (35%) for FY2025-26, subject to AGM approval.
• Record date fixed at Sept 21, 2026.

TDS framework & shareholder details

• TDS on dividends applies at prescribed rates by resident/non-resident categories.
• Resident individuals: no TDS if total annual dividend per folio ≤ Rs 10,000.
• PAN-Aadhaar linkage required; non-linkage may lead to 20% TDS.
• Updated PAN, email, mobile, and bank details must be provided via RTA/DP.
• Dividends paid electronically; physical instruments not used.

Financial results approved

• Unaudited standalone results for quarter ended June 30, 2026 approved by Board.
• Limited Review Report issued by statutory auditors for the quarter.

Audit governance

• Audit Committee reviewed the results before Board approval.
• Board approved results on July 25, 2026 at Vadodara.

Accounting framework and segment

• Results prepared under Indian Accounting Standards and SEBI LODR.
• Single segment business: Pharmaceuticals.

Prior-period adjustments

• Previous quarter figures regrouped/reclassified to align with current period.

Meeting Details

• Meeting on Saturday, July 25, 2026; time and venue not disclosed.

Key Agenda Items

• Consider and approve the unaudited financial results for quarter ended June 30, 2026.

Other Notes

• Trading window closed from July 1, 2026 through 48 hours after unaudited results declaration.

Dematerialisation status and ownership update

• Securities for dematerialisation were confirmed to the depositories (accepted/rejected).
• Dematerialised securities are listed on the relevant stock exchanges.
• Physical certificates were mutilated and cancelled after verification; depository named as registered owner within timelines.

Rating Action Details

• CRISIL reaffirmed the BB+/Stable rating on Mercury Laboratories’ Rs 3 crore fixed deposits.
• Outlook remains Stable.
• Rating agency: CRISIL Ratings.
• Instrument: Fixed Deposits; amount: Rs 3 crore.
• Rationale: moderate risk of default on timely servicing.
• Surveillance ongoing; rating could be revised or withdrawn on new information.
• Material change since last rating: none reported.
• Date: June 30, 2026.

Internal auditor

• M/s K R & Associates re-appointed as Internal Auditor for FY 2026-27.
• Appointment effective May 29, 2026.
• Peer-reviewed partnership firm established in 2009, managed by CA Rachit Shah, CA Keyur Shah, and CA Manish Jethwani.
• Practice areas include risk-based internal auditing, financial due diligence, internal controls, and forensic accounting.

Cost auditor

• M/s V. M. Patel & Associates re-appointed as Cost Auditor for FY 2026-27.
• Appointment effective May 29, 2026.
• Practicing cost accountant firm since 2012, led by CMA Vipin Patel.
• Experience includes cost audit, budgetary control, MIS, and costing.